CEO warns transforming the embattled company is a multi-year process involving incremental steps.
Quebec pharmaceutical will use the proceeds to permanently repay loan debts.
Revenue decline blamed on lower product sales, currency exchange rates and divestitures.
Enhances manufacturing capabilities and export capacity.
Pharmaceutical firm’s lawyer cites an absence of an easily defined class of complainants.
Makers accused of misleading the public about remedy’s short-term effectiveness.
Valeant Pharmaceuticals International Inc. is adding to its dermatology business with the acquisition of Dermik, a dermatology unit of Sanofi, for $425 million.